Drugs / TT-00434
last change Oct 2023 re-read 3 minutes ago

TT-00434

Developed for
cancer
Investigated by
TransThera Sciences (Nanjing), Inc.

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04830501 Jul 2021 → Oct 2023 cancer TransThera Sciences (Nanjing), Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TT-00434 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830501 ↗